Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
November 5, 2020
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone. I’m Junica, and I’ll be serving as your conference operator for today. I’d like to welcome all of you to the Cronos Group’s Third Quarter 2020 Earnings Conference Call. This call is being recorded today. At this point, I’ll hand things over to Shayne Laidlaw in Investor Relations. Please go ahead.
Shayne Laidlaw
executiveThank you, Junica, and I appreciate everyone being here today as we go over Cronos Group's financial and business results for the third quarter of 2020. With me on the call are Kurt Schmidt, our President and CEO; Mike Gorenstein, our Executive Chairman; Jerry Barbato, our CFO; and Xiuming Shum, our EVP of Legal and Regulatory Affairs. This morning Cronos Group put out a news release with our financial results, and those are filed on our EDGAR and SEDAR profiles. That information, along with the prepared remarks, will be posted on our Web site under Investor Relations as well. Before handing things over to Mike, I want to remind everyone that what we discuss on this conference call will include forward-looking statements. Those rest on assumptions subject to risks and uncertainties, and actual results could therefore differ materially from what the forward-looking statements project. This includes as a result of the factors laid out in the cautionary statement and risk factors contained in the company's earnings release and regulatory filings, among them the company's most recent annual report on Form 10-K/A and quarterly reports on Form 10-Q, and any forward-looking statements made during this call are qualified in their entirety by those documents. Also, during this call, certain financial measures may be discussed that are not recognized under the U.S.
Shayne Laidlaw
executiveThe Securities and Exchange Commission calls these non-GAAP measures, which stands for Generally Accepted Accounting Principles. In our view, such non-GAAP figures help management with planning, forecasting, and assessing business and financial performance, including how resources get allocated. You can find reconciliations between these non-GAAP measures and the nearest GAAP measures we report in the earnings press release we furnished to the SEC, and that document is accessible in the press room area of our Web site, thecronosgroup.com. Measures of this kind might not line up with those other issuers use. I also want to mention that today we are hosting this call from our separate remote locations. Because of that, brief delays, cross talk, or small technical problems could occur during the call. We appreciate your patience and understanding ahead of time. We'll now deliver prepared remarks, and after that we'll transition into a question-and-answer session. With that said, I'll hand things over to Mike Gorenstein, Executive Chairman of Cronos Group.
Mike Gorenstein
executiveThank you, Shayne, and good morning to all of you. It's a privilege to address you today in my capacity as Cronos's Executive Chairman. As a lot of you are aware, following careful planning and thorough deliberation, we broadened our leadership team by naming Kurt Schmidt as our new President and CEO in December. I've since moved into the Executive Chairman position, from which I'll head up the board and collaborate with Kurt to keep propelling Cronos Group's strategy forward. I have enormous confidence that Kurt will assist Cronos in building upon our robust history of growth and guide us toward many additional industry-defining achievements. Kurt brings deep experience as a consumer packaged goods leader, with the know-how to take Cronos still further. Across a career spanning more than three decades, Kurt has established a record of delivering exceptional results at several of the most admired global consumer goods companies, among them Blue Buffalo, Nestle, Gerber, and Kraft Foods. He has shown remarkable success in working alongside founders and startups to speed up growth, and we're eager to draw on his expertise as Cronos keeps expanding. When I first met Kurt during my year long hunt for someone to assume the CEO role, it was instantly clear that he is uniquely equipped to steer the company's next stage of growth and to honor our dedication to moving the industry ahead responsibly.
Mike Gorenstein
executiveKurt is deeply committed to what we stand for and to what this remarkable company can achieve. I look forward to working alongside him, drawing on Cronos' strengths, and carrying on with giving our customers brands and products that rank among the very best. This sector may be young, yet that hardly prevents us from gaining wisdom from veteran leaders who come out of nearby industries. Alongside Kurt, we made our senior leadership group even stronger by bringing in Shannon Buggy as Senior Vice President, Global Head of People. Prior to her arrival at Cronos, Shannon served as SVP of Global Human Resources at Nielsen, heading up HR strategy for Nielsen Media. Bringing more than 25 years of experience, Shannon has demonstrated clearly that she can lead and manage human resources teams across the globe. While we get ready for what comes next, making sure our people across the whole organization are well looked after matters more than anything. We have progressed considerably, and the broader industry has changed within a brief span. Working together, we built a business model that is genuinely distinctive, with excellent brands, technology, strategic partners, a solid balance sheet and, crucially, a terrific team concentrated on producing results. When I consider Cronos as it stands now, the opportunities in front of us are plainly more thrilling than they have ever been.
Mike Gorenstein
executiveWe’re eager to keep introducing new cannabinoid offerings in Canada and to build up a collection of U.S. hemp-derived CBD brands. Beyond Canada, we’re looking forward to expanding our products into additional parts of the globe as rules change, and to keep strengthening our position as leaders in the industry. I’d like to express my gratitude to the skilled teams at Cronos, who have gotten us to this point and keep driving us onward. I also want to thank our investors and the analyst community for your dedication to our sector. I know Kurt is eager to collaborate with all of you more closely going forward, and I know everyone will be glad to hear from him on these earnings calls. So with no further delay, I’ll hand the call to our new President and CEO, Kurt Schmidt.
Kurt Schmidt
executiveThanks, Mike, and good morning to all of you. I hope each of you is staying safe and well through these turbulent times. Being able to join two fast paced growth companies with very high ceilings for expansion is a rare thing in a career. My first shot came with Blue Buffalo, which worked out very well, and I think we have a similar opportunity here with Cronos Group to take it to the next level. What Mike and the team have achieved in a short period of time is truly impressive. Cronos is an incredible growth opportunity and new exciting industry. So I couldn't pass up the chance to join the fantastic team to help write the next chapter. I want to thank Mike and the board for bringing me into this family. I appreciate Mike’s trust in me to lead this company he and the team have worked so hard to build, literally from the ground up. Mike has embraced his new role as Executive Chairman, and we are lucky to be able to leverage his vision and expertise as we navigate this continuing evolving industry. Everyone told me that the industry moves at an incredible pace and that one week would feel like one month, and I must admit that is true in the best possible sense.
Kurt Schmidt
executiveDuring the last 2 months, I’ve received an intense introduction to this industry—its difficulties and opportunities—and also to what matters most at Cronos regarding how my background can help move us ahead. For anyone here who isn’t familiar with me, I’d like to explain several of my central convictions and the principles that guide my leadership. I hold the view that we should make high-quality products for consumers, and that brands must be built to go beyond what consumers expect. I have watched organizations unite behind their products and take enormous pride in delivering quality goods to consumers. Cronos’ mission—improving lives by unlocking cannabis’s full potential—matches my fundamental belief in innovation’s power. If we are to prosper and keep succeeding, we must drive change and ensure our innovation efforts remain at the leading edge of this emerging industry. I likewise believe in a winning team, along with the work ethic and accountability such a team brings. I believe in what people inside an organization can do to cultivate a culture centered on quality, innovation, and mutual support and recognition. At heart I am a brand builder, and I have substantial experience in regulated markets as well as upstart ones. Brands are something I care deeply about, and Cronos inspires me.
Kurt Schmidt
executiveTaking on the CEO role gives me a chance to apply my background in brand building to this organization — to strengthen the portfolio we already have and the high-performing teams behind it so we can deliver results. Something I've come to understand during these first few months is that our brands carry extraordinary potential. Our Chief Innovation Officer, Todd Abraham, along with his team — supported by marketing, sales, and numerous other functions across the company — is doing outstanding work getting new and innovative products into the markets where we operate worldwide. Todd and I share comparable experience from working at large-scale CPG companies. I'm eager to collaborate with him as we keep developing a CPG infrastructure for innovation and brand marketing at Cronos. When it comes to Canada, I'm looking forward to soon providing further specifics about innovation launches aimed at the adult use market. Under Todd, our innovation team has been working hard to refine the next generation of product for our brands. As the Canadian market keeps expanding in both sophistication and size, reaching more consumers with those products is a priority for me. In the US hemp derived CBD market, I'm looking forward to supporting Lord Jones, our luxury CBD brand.
Kurt Schmidt
executiveAnd even with how things have gone lately, we’re still sure we can expand the brand portfolio in the U.S. market for CBD derived from hemp. There’s a chance for us to boost how this brand is doing as we aim to deliver innovative items to adult buyers through DTC as well as brick and mortar channels. I’ve begun digging into this business, assessing strengths and opportunities alike, and I think I can draw on my experience to help steer it toward greater success down the road. Last month we introduced Happy Dance, a new CBD skincare and personal care brand that actress and New York Times bestselling author Kristen Bell co-founded. This new line includes a body butter, a coconut milk and a bath bomb, each made with ingredients Kristen Bell loves and premium full spectrum hemp derived CBD abstracts. Launched at first via the DTC channel, we intend to move into brick and mortar in the future. Happy Dance products fit perfectly for CB enthusiasts and for anyone trying CBD for the first time. Though it’s still in its early innings, our U.S. team has performed phenomenally during the launch phase. And on top of that, we’re encouraged by how positively consumers are responding to Happy Dance.
Kurt Schmidt
executiveTurning now to what we're doing in Israel. After dried flower went on sale there in the second quarter under the PEACE NATURALS brand, I'm glad to say Cronos Israel now holds every certification needed to cultivate, produce and market pre rolls and oils too, and since October Cronos Israel has been selling PEACE NATURALS branded dried flower and oils in that market. COVID has kept me from visiting our Israeli operations, but we've held many virtual team meetings, and I'm eager to work alongside them face to face. We have a great chance to lead in this fast-growing medical market, and in the potential adult use market once it opens. I've spent time with Todd and our partners at Ginkgo on our fermentation work. Having been a pharma executive, I bring considerable experience with fermenting key gradients, and this project excites me given how transformative it can be. Progress so far pleases me, and I look forward to sharing further updates down the road. I share the view that this project can transform our business, both on margins and on the innovation side.
Kurt Schmidt
executiveOur confidence is unchanged in the initial goal we set: reaching commercialized scale for cannabinoids by September 2021, a milestone that will let fermented cannabinoids go into finished products down the road. Turning to the US election, our company — like many of you on this call — is eager to watch how things develop when it comes to cannabis regulation and legalization. No matter which party holds the various branches of government, this election made it obvious that cannabis keeps gaining popularity throughout the United States, and that extends the positive momentum the industry has been enjoying. It's good to see that in red states and blue states alike. Every adult use and medical cannabis ballot initiative is advancing, and for the industry that counts as a win. We're monitoring it carefully and putting together plans so we'll be ready for a range of possible scenarios. Like Mike, I'm focused on creating long term shareholder value through developing disruptive intellectual property and building iconic brands. And just as Mike does, I want to encourage long term thinking, particularly given today's economy. Cronos is building for the future. Our value will come from technology breakthroughs and branded sales that help us establish relationships with our consumers. This organization has top tier talent, and I'm excited to lead this impressive team into the next phase of growth.
Kurt Schmidt
executiveHaving said that, I'll hand things off to Jerry Barbato, our CFO.
Jerry Barbato
executiveThanks, Kurt, and good morning to everyone. Now moving on to the financial results. For the third quarter of 2020, consolidated net revenue came in at $11.4 million, which represents a 96% rise compared with the same period a year earlier. The year-over-year revenue growth was mainly fueled by continued expansion in Canada's adult use cannabis market. This was partly offset by non-recurring wholesale revenue in the Canadian market during Q3 of 2019, along with strategic price cuts on various adult use cannabis products in certain Canadian provinces during the third quarter of 2020, while contributing factors included consolidating Redwood's financial results — our US hemp derived CBD business acquired in September of last year — and sales of PEACE NATURALS branded cannabis products into the Israeli medical market. Consolidated gross loss for the third quarter of 2020 totaled $1.5 million, which is a $1.6 million reduction in losses compared with the third quarter of 2019. That improvement over the prior year came mainly from higher revenue and the incremental gross profit contributions of the Redwood acquisition, offset by an increase in cost of sales, driven largely by a greater volume of adult use sales and the related third-party purchase flower, as well as a decline in wholesale sales. Reported operating loss for the third quarter of 2020 was $41.2 million, which reflects a $10.5 million increase in losses versus the third quarter of 2019.
Jerry Barbato
executiveThe year-over-year rise came mainly from higher share-based payments tied to separation agreements involving Redwood employees. Additional factors included a full quarter of results from our US segment, greater G&A expenses — including review costs and costs stemming from the company's restatement of its 2019 interim financial statements — along with higher sales and marketing costs, largely for brand development, plus R&D spending, all partly offset by the improvement in gross loss. Now to our reporting segments. For the rest of the world segment, net revenue in the third quarter of 2020 came in at $9.7 million, up 90% versus the prior year period. That year-over-year revenue growth was driven mainly by continued expansion of the adult use Canadian cannabis market and by sales of PEACE NATURALS branded cannabis products into the Israeli medical market, partly offset by non-recurring wholesale revenue in the Canadian market in Q3 2019 and by strategic price reductions on various adult use products in certain Canadian provinces during the third quarter of 2020. A quick look at the expansion in the Canadian cannabis market: we're encouraged by the ongoing growth of new retail locations in provinces such as Ontario, which gives consumers more convenient options to purchase cannabis products responsibly.
Jerry Barbato
executiveFor our rest of world segment, gross loss came in at $2.2 million, which is a $1.4 million reduction in losses compared with the third quarter of 2019. That year-over-year improvement was mainly the result of higher revenue, partly offset by rising cost of sales, which came from a larger volume of adult use sales along with the related third party flower purchases, plus a drop in wholesale sales. As we work through 2020 and beyond to build an efficient global supply chain for this rest of world segment, we expect gross margin to keep fluctuating as price and mix shift from one quarter to the next. The reported operating loss for the rest of world segment in the third quarter of 2020 was $18 million, which represents a $3.2 million decrease in losses versus the third quarter of 2019; that improvement was mainly driven by lower general and administrative costs, which came from a reclassification of $4.6 million in corporate expenses in the third quarter of 2020 that had no effect on the company's consolidated statement of net income, and by an improvement in gross loss, partly offset by higher R&D spending. Now turning to the US segment. Reported net revenue for the third quarter of 2020 was $1.6 million, up 143% from the third quarter of 2019.
Jerry Barbato
executiveThe year-over-year rise mostly comes from having a full quarter of results in Q3 2020 versus 25 days in Q3 2019. Yes, there was some softness tied to COVID restrictions, but we won't use that as an excuse, and we're not happy with how we performed in the US. Looking ahead to Q4 and past it, we've overhauled our advertising and promotional work, with Kurt involved in the Q4 plan, and mapping out what we must accomplish in 2021 has helped the team. Todd's group has also stepped up more in the US business, which we believe will produce positive results over time. And as Kurt noted, we introduced our new brand, Happy Dance, in October. We're eager to bring that new brand and its excellent products to a wider audience. Gross profit for the US segment came to $0.7 million, a gross margin of 41%. The reported operating loss in the US segment for Q3 2020 was $12.2 million. That loss mainly stemmed from higher share-based statements tied to separation agreements with Redwood employees; sales and marketing costs incurred for developing and launching the Happy Dance brand, plus new products under the Lord Jones brand; and greater general and administrative expenses, driven by salaries and wages supporting growth initiatives across various functions, partly offset by higher gross profit.
Jerry Barbato
executiveOn the whole, Cronos Group posted lower net income compared with the same period a year earlier. The main driver was the change in fair value of the financial derivative liability tied to Altria's investment, and the 10-Q discusses that in greater detail. During 2020's third quarter, the company booked a non-cash gain of $105.3 million connected to the change in fair value of those financial derivative liabilities. Cronos still anticipates substantial volatility in reported earnings, largely because of quarterly fair value adjustments linked to movements in Cronos Group's stock price. Moving to the balance sheet: the company finished the quarter with roughly $1.3 billion in cash and short-term investments, essentially unchanged from 2020's second quarter. Capital expenditures during the quarter came to $8.3 million. That outlay covers investments in Cronos Fermentation, the PEACE NATURALS campus, our Israeli facility, and our new ERP system. We stay dedicated to putting capital to work in a disciplined way and solely in manners consistent with our strategic priorities. Next, I'd like to give an update on the remediation work concerning the material weaknesses we disclosed in our fourth quarter of 2019 filings.
Jerry Barbato
executiveAs a company, we're dedicated to putting the best practices in place for financial reporting. Internal testing has been finished by our management, with oversight from the audit committee, on each of the eight controls laid out in its remediation plan. Testing by our independent auditor is underway on certain controls and will move on to the remaining controls over the course of 2020. Finally, after our new ERP system went live in July across our Canadian business, we've also begun efforts to extend the reach of that ERP system to our US business, which we expect to launch in the first half of 2021. The work our teams are doing around the world continues to encourage me. With that, I'll hand things over to Kurt for closing remarks before Q&A.
Kurt Schmidt
executiveThank you, Jerry. During these initial months at Cronos, the depth of talent across the company has given me real encouragement. I'm eager to take the experience and lessons I've collected over my career and bring them into this sector, helping Cronos become a long-term leader in cannabis. Cronos rests on a foundation built to drive full change in the industry. We'll keep leading on innovation while taking calculated risks that move this industry forward responsibly. The team, the leadership, the organizational capabilities and the financial strength are all in place for us to be a leader in the cannabis industry. And I'm excited to lead Cronos on this journey. With that, let's now open the lines for questions.
Operator
operatorAnd our first question is coming from John Zamparo at CIBC.
John Zamparo
analystCould you help us understand more clearly what's driving gross margin up and down, and when you finally expect it to become positive — whether that's on a consolidated basis or by region? Thanks.
Mike Gorenstein
executiveYou really need to distinguish the two situations—Canada versus the US. In Canada, what we're observing is ongoing price deflation throughout the Canadian cannabis market, with many producers cutting their net prices and introducing bigger package formats. We conducted our own internal analysis, examined our brands, and benchmarked them by product category against our competitors, and we've reduced certain prices—differently in each province—so it's been quite strategic. And as we keep refining our global supply chain through 2020 and into 2021, we anticipate that gross margins will keep fluctuating, since pricing and mix can shift quarter to quarter. In our US business, the picture is somewhat different. We experienced heightened promotional activity tied to COVID. That promotional activity came down in the third quarter. Margins improved sequentially. And we stay confident about the long-term viability of this US CBD market. And another thing you saw, I think, was some premium pay when COVID hit in the second quarter, which was phased out across the third quarter. But I think you'll see the same pattern—we've launched a new brand, and margins will continue to fluctuate depending on mix.
Kurt Schmidt
executiveLet me add one thing there. What I believe you’re observing is that the price deflation really stems from where inventories stand. So that’s an issue folks are still working through. And once that clears up, in my view it’s a near-term issue rather than something longer lasting.
John Zamparo
analystMy second question is broader and focuses more on your M&A strategy, especially in the US. We're still somewhat uncertain about the election. But if there's a split between the White House and Senate, maybe we don't get that transformational reform you need to get cannabis off the Controlled Substances Act. So in that scenario, does that make you think differently about M&A — do you start perhaps looking at other countries with more urgency, or do you maybe push the gas pedal a little more on CBD? I'd just like to get your sense of how potential regulatory reform, or a lack of it going forward, changes your strategy over the next 12 to 18 months?
Kurt Schmidt
executiveOn the first half, clearly our balance sheet gives us a degree of flexibility. And no matter what political shifts occur in the US, the regulatory environment keeps changing, and we are assessing it. One thing that matters a great deal regarding the changes we have made is moving Mike into the Chairman position — Mike's focus, and he can address this himself, will be on our US strategy. I cannot imagine a better individual for that role, able to steer us through this. So I believe that is significant, and I believe that is significant as a strategic market versus considering other markets at this time. So Mike, I don't know whether you would like to add anything.
Mike Gorenstein
executiveTo echo Kurt exactly, the end game has always been the focus for us and for me. The US THC market is our number one priority, and we expect it to be the biggest profit pool. As we look at various scenarios and structures, the question is how we enter, not whether we enter, and naturally the regulatory environment will dictate the when and the how, but it is top of mind for us.
Operator
operatorAndrew Carter from Stifel is on the line with our next question.
Andrew Carter
analystI'd like to dig deeper into that gross margin question, since we all observe the pricing pressure on flower and get that you're reducing your prices somewhat to keep the gas aligned. What isn't clear to me, though, is the third party costs, and you brought up a lot of inventory. Is this a situation where third party high quality flower costs aren't coming down at the same pace? My question, I suppose, is whether that applies just to—are you upside down on prices? And how do you expect that to ease, in terms of the high quality flower and being able to bring your supply chain in line so that you've got the cost to serve the Canadian adult use market?
Mike Gorenstein
executiveSure, I’ll let Jerry add his thoughts too, but on that pricing matter from two quarters back. So going forward, I think you’re seeing improved raw material pricing. But we still — we’ve got that inventory left over from before, so I expect it to work itself out as we move ahead, as demand becomes more aligned — supply becomes, sorry, more aligned with the demand side. Jerry?
Jerry Barbato
executiveAndrew, let me tack on a bit more here. What we're observing is that for our third-party purchases, the cost per gram is declining, even for the high-quality, high-THC product. That said, we truly need to split that inventory between flower and oil, and by where it's headed, and we apply a weighted average cost. So over time, that cost is going to come down. But as I mentioned and Kurt has noted, over the near term, there are simply plenty of deflationary pressures in the Canadian market that we need to work through.
Andrew Carter
analystSecond, I'd like to ask about Israel. I believe you mentioned 500,000 in sales from outside North America. My estimate is that Israel is roughly a $250 million annualized market, so I'd like to understand what that business could look like next year. Could Israel essentially be a bigger growth driver next year than Canada? Thanks.
Kurt Schmidt
executiveOur outlook on Israel is genuinely optimistic. Look, it's still early days. Even so, the number of patients keeps climbing. We therefore expect that to expand at a fairly rapid pace. And our position there is quite strong. We've recently obtained the certifications needed for growing and producing, plus marketing, dry flower, pre rolls and oil drops in Israel. And at this point we're selling dried flower and oils under the PEACE NATURALS brands, which have gotten a warm reception. So we're quite bullish about that market. I'd rather not speculate on how large I think it will become. One lesson this industry has taught me is that making forecasts from estimates isn't simple. Still, we're pleased with the direction it's heading. We're pleased with where the legal environment is heading. We're pleased with how actively the Israeli government engages with the industry and backs it. So this strikes me as a very solid opportunity, and we have a very solid team on the ground.
Andrew Carter
analystAppreciate that. I'll make sure it gets to the right people.
Mike Gorenstein
executiveTo add to that point, I would say that, directionally, the situation in Israel is extremely positive. So you are seeing great momentum, not only in the medical market but also in regulatory progress. So I think that within the framework we have today, there is a great growth opportunity, but part of what Kurt spoke about — why forecasting is so hard if CBD is descheduled or if adult use opens up — is that this certainly makes it an exponentially larger growth opportunity.
Operator
operatorVivien Azer from Cowen is up next with a question or comment.
Vivien Azer
analystMy first question follows up on one of the earlier ones. It's just a point of clarification, if you will, Mike, and I think it's directed at you. What did you assume in your base case if there were a blue wave? Because like our house, you surely weren't descheduled even if the Democrats won the Senate and the White House, right? So I'm curious whether you share that view or whether you're a bit more optimistic?
Mike Gorenstein
executiveI mean, that comes down to timing, in my view. One key point — and this has always been my position — was to get beyond the election and let everyone, from a purely political standpoint, sit down and examine the optimal approach for establishing regulations and policies, be it a stimulus or developing industries that assist in rebuilding part of what the economy shed during the last year. Doing that during an election year is extremely hard. So from our standpoint, it wasn't an — if something occurred right after, I believe that invariably sounds superior to what actually happens in practice. Still, moving beyond the election served as a major catalyst no matter who prevailed — blue waves, split — and I believe we'll witness that beginning with stimulus. And I think with cannabis, as you observe with the ballot initiatives, red or blue, wherever popular opinion lies, you notice the demand for jobs, we require tax revenue, we need social justice reform, and there exists a quite straightforward and elegant answer, which is moving cannabis legislation forward.
Kurt Schmidt
executiveAlso, another positive aspect of this business is that our team in Washington is heavily involved with these matters. As a result, we have strong confidence that we will be in a position to see the possible paths it could take.
Vivien Azer
analystMy real question concerns the strategic pricing changes implemented during the quarter. Could you elaborate on that a bit more? Specifically, I'd like to know how you approached the size of those pricing changes and what served as your benchmark — was it competitor pricing, handling price caps, price elasticities, or price caps versus the illicit market? Any additional detail would be useful. Thank you.
Jerry Barbato
executiveAs is common across most CPG companies, we routinely conduct a strategic review of the market and examine how our brands—both COVE and Spinach—differ by product format and price point. Through that process, we determined that we wanted to align our pricing more closely with the competitive set we're targeting. So we made adjustments to fit our respective brands better into that group. These pricing changes have been in place for just a few months, and we're seeing some early positive results, but we'll keep evaluating the situation and make further adjustments as we see fit.
Operator
operatorOur following question is from Rahul Sarugaser at Raymond James.
Rahul Sarugaser
analystMy first question really concerns Lord Jones, Happy Dance, and Jerry, especially since I'm very pleased with how the CBD products have ramped up. Given that the US CBD market is fairly fragmented, with most offerings coming from what are essentially cottage industry brands, what's your plan to set yourselves apart—or what I take to be your major brands—from those smaller cottage industry players, and when might we begin to see something like an inflection point in US revenue?
Kurt Schmidt
executiveAt bottom, we have faith in our brands. With Lord Jones, clearly, last quarter's results didn't please us. Still, we're confident the right plans are in place to fix that. Our emphasis is squarely on branding and the branding experience. COVID, of course, has struck the CBD segment harder than the THC side. On innovation — we're constructing an innovation funnel. We're examining our marketing mix model to ensure we're reaching the right touch points. As for Happy Dance, it has us quite excited. These are early days. That said, the launch was thrilling and executed well. At the start — we're in the early innings, yet momentum has genuinely been positive, and we intend to carry it forward.
Rahul Sarugaser
analystMy next question, then, concerns fermentation. It's been three quarters now since you laid out your projection for Cronos' initial products to come out of the fermentation facility. Is that timeline still on track? Are there particular product formats we ought to be considering? And given the differing regulatory frameworks for cannabinoids beyond CBD in each market, how does Cronos intend to slot these products into Canada as opposed to the US?
Kurt Schmidt
executiveYes, we remain on schedule. We're nearing that point. Our expectation is that we will turn out our initial CBDA product, which has properties comparable to CBD. And our goal has been, and still is, to generate fermented cannabinoids at commercial scale in September of 2021. Following that, we'll move on to fermented cannabinoids being used in finished products. Clearly Canada comes first, though we'll need to work out the regulatory landscape. But this represents a crucial strategic foundation. So we're eager for that, and we will — we are on track, and you ought to begin seeing that by the end of September of '21.
Mike Gorenstein
executiveTo build on that point, I want to stress again that we really do see fungibility when it comes to our supply chain. So in terms of derivative products and the way we'll utilize fermented cannabinoids, it doesn't have to be an entirely new product format. Without revealing our 2.0 product pipeline, that format could be something you've seen before. We're using fermented cannabinoids, and it could be something launched at a later point. We view it as something we can integrate fully into our supply chain. And on the US side, the key distinction we'll be considering is whether the cannabinoid in question falls under the Controlled Substance Act or not. So some of those cannabinoids, THC and THCB, we believe would be covered, but CBD and CBG, of course, we believe would not be.
Operator
operatorThe following question is from Tamy Chen at BMO Capital Markets.
Tamy Chen
analystI think nearly everything I wanted to ask has already been covered, so there's just one left. At this stage I'm simply wondering — compared with some of your competitors up in Canada, your footprint there is on the smaller side. So I'd like to know whether anything intriguing is starting to show up in that market right now that might justify putting more money in or making an acquisition?
Kurt Schmidt
executiveOur brands are something we have confidence in, and when I think about performance — take Spinach as an example — we see considerable runway ahead, and the growth across our brands will be driven through presence in the market and the innovation funnel that we have. On M&A, I'm not really going to comment. I won't address that on this call, but we are always on the lookout for opportunities. And should something make sense for us and align with what we're trying to do, we have the capability to act on it.
Operator
operatorWe now move to Graham Kiebler from Eight Capital for the following question.
Patrick Sullivan
analystAppreciate you taking the question. Patrick Sullivan here, actually, calling in on behalf of Graham. Most of what I had has already been covered, but I suppose I'd like to revisit the CBD part of the business once more. You mentioned that you were doing a refresh — the marketing campaign, with certain direct inputs, as I understand it. I'm curious whether you could expand on that a bit further. Within those strategies, what exactly are you attempting, or what are some of the items currently in the pipeline on that front? Thank you.
Kurt Schmidt
executiveMy view is that this simply speeds up what the team has already been pursuing. So once more, that’ll come on the marketing investment front, on the distribution front, and on the innovation front as we set out the innovation funnel, which is going to be an important element. And you’ll see that take shape over the coming 12 months.
Operator
operatorThe last question is going to come from Bill Kirk at MKM Partners.
Bill Kirk
analystAppreciate you taking my question. Mine has to do with reporting adjustments — I just want to clarify a few things. Was the US separation equity comp adjusted out of the adjusted operating loss for the US segment? From what I can tell, it doesn't look that way, but then I notice the share-based comp adjustment to consolidated EBITDA. So I suppose could you help me get a handle on how that US separation comp was handled in the adjustments segment figure as opposed to the adjusted consolidated EBITDA figure?
Jerry Barbato
executiveNo, we didn't strip it out. So that adjusted operating loss for the US segment does include it. And for consistency's sake, we remove share-based comp when calculating our adjusted EBITDA figure.
Bill Kirk
analystJust to clarify, that's not at the segment level but at the consolidated level?
Jerry Barbato
executiveThat figure has been reconciled to the consolidated EBITDA number. That's right.
Operator
operatorThat appears to be all the questions we have lined up. Would anyone like to offer any final comments before we wrap up?
Kurt Schmidt
executiveNope. I’ll simply say thank you to everyone, and I’m eager to collaborate with each of you going forward.
Operator
operatorThat brings us to the end of today's conference call. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.